Y-mAbs Therapeutics, Inc. today announced a clinical update on omburtamab for the treatment of diffuse intrinsic pontine glioma (“DIPG”). Data was presented at the Society for Neuro-Oncology (“SNO”) Virtual Annual Meeting held November 19 through November 21, 2020. The omburtamab data was presented by Dr. Evan Bander from Weill Cornell Medicine.
In a poster presentation, Dr. Bander presented infusion related data from the ongoing Phase 1 study in DIPG. The study showed the possibility of repeated convection enhanced delivery (“CED”) infusions into the pediatric brainstem. Past CED treatments did not negatively influence the procedural workflow, technical application of the targeted interface, accuracy of catheter placement or distribution capacity. In the study, seven patients underwent two or more sequential CED infusions.